This combination, marrying the strengths of a third-generation cephalosporin with a non-beta-lactam beta-lactamase inhibitor, represents an advanced frontier in the battle against MDR-EB infections.[23] Its potential benefits, especially in scenarios where other therapeutic interventions have been faltered. Here, LACTB is linked to epidermolysis bullosa.